Physician profile
Ashton Fields
NPI 1598129751
$2,856.11
in general payments reported to CMS, 2019-2025
24 companies · $739 in 2025
The $739 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.52 · 2022: $424 · 2023: $916 · 2024: $735 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,390.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $708.37 | 2022-2025 | |
| Novo Nordisk INC | $428.07 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $418.10 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $251.76 | 2022-2025 | |
| Lilly USA, LLC | $167.17 | 2022-2025 | Jardiance, Zepbound, Emgality |
| Abbott Laboratories | $150.13 | 2022-2023 | Freestyle Libre 3 |
| Pfizer INC. | $110.71 | 2022-2025 | |
| Exact Sciences Corporation | $103.26 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $69.15 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $55.93 | 2022-2023 | Shingrix |
| Biohaven Pharmaceutical Holding Company Ltd. | $52.95 | 2022 | |
| Janssen Pharmaceuticals, INC | $49.15 | 2022-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.85 | 2023-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.04 | 2023-2024 | Xifaxan, Trulance |
| Cranial Technologies, INC | $28.23 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $26.45 | 2024 | Cios Spin |
| Corcept Therapeutics | $22.71 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $20.51 | 2024 | Gardasil, Gardasil 9, Vaxneuvance |
| Inspire Medical Systems, INC. | $20.36 | 2024 | Inspire |
| Antares Pharma, INC. | $18.04 | 2025 | Xyosted |
| Biogen, INC. | $17.48 | 2025 | Skyclarys |
| Novartis Pharmaceuticals Corporation | $16.93 | 2025 | |
| Xeris Pharmaceuticals, INC. | $14.26 | 2025 | Keveyis |
| Dynavax Technologies Corporation | $13.50 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashton Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.